A Study to Assess the Short-Term Efficacy and Safety of Olanzapine and Fluoxetine Compared to Placebo and Fluoxetine for Nonpsychotic Treatment-Resistant Depression
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Fluoxetine (Primary) ; Olanzapine (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 05 Feb 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 11 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Nov 2015, according to ClinicalTrials.gov record.